Product Description
Mechanisms of Action: TXA2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Beijing Rundekang Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: India
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Pneumonia|Respiratory Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05706454 |
RAMBAN-1 | P3 |
Recruiting |
COVID-19|Respiratory Tract Infections|Pneumonia |
2024-07-01 |
16% |
2023-02-01 |
Primary Endpoints|Treatments |